Skip to main content
main-content

Early-stage NSCLC management – surgery, targeted treatment and immunotherapy

Making sense of the rapidly changing treatment landscape for patients with early-stage NSCLC

28-04-2022 | Non-small-cell lung cancer | Video

The role of surgery in early-stage NSCLC management

Speaker: Jessica Donington

Jessica Donington gives a surgeon’s perspective on the treatment of early-stage NSCLC in the era of targeted and immunotherapy options and the importance of helping patients to RIOT.

00:00 Introduction
01:25 Biomarker testing 
03:24 Adjuvant and neoadjuvant immunotherapy
10:10 Unmet needs 
13:35 The current role for surgeons 

Transcript


Meet the faculty

13-04-2022 | Non-small-cell lung cancer | Video

PD-L1 expression in early NSCLC: Interpreting the data so far

Speakers: Heather Wakelee and Nasser Altorki

Heather Wakelee and Nasser Altorki discuss the current position on PD-L1 expression and immune checkpoint inhibition in early-stage, resectable NSCLC.

00:00 Introduction 
03:26 PD-L1 testing considerations 
08:47 PD-L1 and the immunotherapy trial findings 
26:08 Dual immunotherapy? 
27:11 Choosing between the options

Transcript


Please feedback


Thank you for watching, please take a moment complete our short survey.

Faculty disclosures

Faculty disclosures

Jessica Donington

Dr Jessica Donington is a speaker for AstraZeneca and has financial relations with the following companies to disclose: Bristol-Myers Squibb and Genetech Inc. All of the relevant financial relationships listed for these individuals have been mitigated.

Heather Wakelee

Heather Wakelee discloses the following relationships and financial interests. She has been an invited speaker, has participated in compensated activities, has received financial support/sponsorship from Companies including: ACEA Biosciences; Arrys Therapeutics; AstraZeneca/Medimmune; BMS; Clovis Oncology; Genentech/Roche; Merck; Novartis; Seagen; Xcovery; Helsinn; Janssen; Daiichi Sankyo; Blueprint; and Mirati.

Nasser Altorki

Nasser Altorki received grants or contracts from AstraZeneca, Janssen, the National Cancer Institute, New York Genome Center P1000, and the US Department of Defense. 

He has received honoraria from AstraZeneca and Regeneron.

Funding and disclaimer

Funding and disclaimer

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Any information provided and opinions expressed do not necessarily reflect the views of Springer Healthcare Limited (part of the Springer Nature Group) or the Medicine Matters Editorial Board. Springer Healthcare Limited, Springer Nature Limited and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox

Attention: This content is intended for healthcare professionals only

In order to proceed please confirm whether you are a healthcare professional.

No, I am not a
healthcare professional
Yes, I am a
healthcare professional